Analytical Data
-
基因名
OSMR-GPL fusion
- Application
-
种属
Human
-
表达系统
HEK293
-
标签
C-8*His
-
纯度
Greater than 90% as determined by SDS-PAGE.
-
蛋白编号
Q99650 (M1-A428)&Q8NI17
-
表达区间
Q99650 (M1-A428)&Q8NI17 ( L21-E225)
-
分子量
110-140 kDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
OSMR-GPL fusion proteins are the subject of significant research interest due to their potential implications in cancer biology and treatment. OSMR (Oncostatin M receptor) is a member of the class I cytokine receptor family, which plays a critical role in various physiological processes, including cell proliferation, differentiation, and survival. It has been increasingly recognized that aberrant signaling through OSMR may contribute to tumorigenesis and cancer progression. The GPL (glycosylphosphatidylinositol-anchored protein) is another important component, frequently involved in membrane anchoring and signal transduction. The fusion of OSMR with GPL is envisioned to enhance the stability and functionality of OSMR in cellular contexts, potentially leading to novel therapeutic avenues in oncology. By studying OSMR-GPL fusion proteins, researchers aim to elucidate the mechanisms underlying OSMR-mediated signaling and its effects on cancer cell behavior. The exploration of these fusion proteins may also unveil new biomarkers for cancer diagnosis and targets for drug development, thereby addressing the pressing need for effective cancer therapies.
